Berberine and Cinnamon in Management of Diabetes

National Nutrition and Food Technology Institute44 enrolled

Overview

In this randomized clinical trial, patients with diabetes will be randomly assigned to receive either Berberine, and Cinnamon supplements or placebo for 12 weeks. Then the glycemic characteristics will be compared in two groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Diabetes

Interventions

Berberine+Cinnamon (TDS)DIETARY_SUPPLEMENT

The supplements contains 400 mg Berberine, and 200 mg Cinnamon extract

Placebo (TDS)OTHER

Placebo contains Maltodexterin

Eligibility

Sex: ALLMin age: 20 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 30-70 years * Diagnosed type-2 diabetes mellitus (based on American Diabetes Association criteria) Exclusion Criteria: * Patients with an allergy to berberine /cinamon * Lactation, pregnancy * Patients with any malignancy * Patients with unrelated chronic illness * Patients with cardiac, liver or respiratory failure

Locations (1)

Azita Hekmatdoost

Tehran, Middle East, Iran

Outcomes

Primary Outcomes

HbA1C

HbA1C change from baseline

Time frame: 0 and 12th week

Secondary Outcomes

Fasting blood sugar

Blood sugar change from baseline

Time frame: 0 and 12th week

Lipid profile

lipid profiles change from baseline

Time frame: 0 and 12th week

Anthropometric measurements

weight, height, BMI, WC

Time frame: 0 and 12th week

Blood Pressure

measuring according to the BP measurement guideline

Time frame: 0 and 12th week

CRP

measuring the blood concentration of C-reactive protein

Time frame: 0 and 12th week

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.